Background-Cardiac development is a complex process resulting in an integrated, multilineage tissue with developmental corruption in early embryogenesis leading to congenital heart disease. Interrogation of individual genes has provided the backbone for cardiac developmental biology, yet a comprehensive transcriptome derived from natural cardiogenesis is required to gauge innate developmental milestones. Methods and Results-Stage-specific cardiac structures were dissected from 8 distinctive mouse embryonic time points to produce genome-wide expressome analysis across cardiogenesis. With reference to this native cardiogenic expression roadmap, divergent induced pluripotent stem cell-derived cardiac expression profiles were mapped from procardiogenic 3-factor (SOX2, OCT4, KLF4) and less-cardiogenic 4-factor (plus c-MYC) reprogrammed cells. Expression of cardiacrelated genes from 3-factor-induced pluripotent stem cell differentiated in vitro at days 5 and 11 and recapitulated expression profiles of natural embryos at days E7.5-E8.5 and E14. 
mbryonic development of the heart encompasses a complex orchestration of events deployed in a predictable and sequential pattern. [1] [2] [3] [4] Disruption of these organized events leads to developmental abnormalities underlying congenital heart disease, 5, 6 comprising a variety of manifestations for which molecular fingerprints are being actively investigated. [7] [8] [9] With the intricacy of cardiac development, most studies focus on the dissection of discrete cardiogenic pathways as well as localized interactions between limited numbers of factors. However, integration of the multiple simultaneous processes and networks defining embryonic development of the heart is required to extend the molecular understanding of cardiac differentiation and congenital heart disease. Current knowledge based on comprehensive expression analysis of genes responsible for specific components of cardiac specification 10, 11 would benefit from genome-wide approaches using native tissue platforms to create a spatiotemporal expressome, reflecting natural cardiac development.
Clinical Perspective on p 471
Gene expression cascades, regulating the development of chamber-specific features of the heart, are incompletely recapitulated during in vitro cardiogenic differentiation of pluripotent stem cells 12 in part attributable to inconsistent cell culture conditions that expose the inevitable variability between stem cell lines. With the advent of induced pluripotent stem cell (iPSC) technology, sources for pluripotent stem cells have significantly expanded, providing a wide range of reagents to re-create patient-specific cardiac tissue. 13, 14 However, nuclear reprogramming has been shown to impact downstream cardiogenicity of iPSC, [15] [16] [17] [18] [19] giving rise to lines with variable cardiogenic potential and threatening the reproducibility of disease-specific model systems. As the demand increases for disease-in-a-dish modeling efforts, bioengineered cardiac progeny are essential for the advancement of mechanistic and drug toxicity studies and ultimately safe and effective cell-based therapies for cardiovascular disease. [20] [21] [22] Therefore, a systematic understanding of natural cardiogenesis and the ability to target novel molecular switches that regulate the differentiation of the ventricular myocardium are required to identify conserved patterns of sequential gene expression. The molecular blueprint of ventricular myocardium could improve our understanding of deficiencies leading to congenital syndromes and augment the resources for regenerative strategies as well as disease modeling and drug testing. A cardiogenic roadmap calibrated according to natural embryonic cardiac tissue would establish developmental milestones and innate mechanisms to gauge normal and abnormal cardiogenic processes within bioengineered cardiac progeny.
Herein, we leverage the genome-wide transcriptome of innate cardiac developmental biology in the mouse model and validate the use of this spatiotemporal roadmap as a tool to predict in vitro cardiogenic potential of independent iPSC lines. By extracting a set of developmentally regulated genes that are differentially expressed in undifferentiated pluripotent lines stratified according to high and low functional cardiogenic potential, we have developed a predictive indicator of downstream cardiogenicity applicable for probing individual iPSC lines. The ability to diagnose and discriminate iPSC clones according to pathways conserved in native cardiogenicity provides an innovative approach to select individual cell lines for disease modeling, drug testing, and ultimately the efficient production of stage-specific cardiogenic progeny for personalized regenerative applications.
Methods

Tissue Dissection and RNA Isolation
Staged mouse embryos were harvested from timed mating pairs and confirmed using morphology and somite count as inclusion criteria for each developmental time point. Whole embryos (E7.5), heart tubes (E8.5), or left and right ventricles (E9.5, E12.5, E14.5, E18.5, and newborn and adult mice) were microdissected and pooled into triplicate sample sets; ≈30 to 50 embryos/hearts were included in each replicate for E7.5, E8.5, and E9.5; 10 to 20 hearts were collected per E12.5 or E14.5 sample; 3 to 5 hearts were pooled for each E18.5 replicate; and 1 heart was used for newborn and adult samples. R1 embryonic stem cells (ESC) were used as pluripotent reference. RNA was extracted using the Qiagen RNeasy kit. Because of high protein content and larger size of samples corresponding to newborns and adult animals, samples were fast-frozen and pulverized to optimize digestion in the first steps of the RNA extraction process.
Cell Reprogramming
iPSC lines used for transcriptome analysis were derived from mouse embryonic fibroblasts exposed to viral cocktails containing either 3 (SOX2, OCT4, and KLF4) or 4 (plus c-MYC) reprogramming factors. 16, 18, 23 Infective units were composed of pEX-QV (GAG/POL) expression vector and pMD-G packaging plasmid with individual expression constructs: psin-c-MYC, psin-KLF4, psin-OCT4, and psin-SOX2. 23 Five days after infection, cells were replated onto mitomycin-inactivated feeders and cultured in mouse ESC medium containing leukemia inhibitory factor for 2 to 4 weeks. Compact and round colonies emerged within 2 weeks for 4-factor-reprogrammed cells or 3 to 4 weeks for 3-factor-reprogrammed cells. These colonies were individually picked and grown on inactive feeders in leukemia inhibitory factor-containing medium. Cell lines were split every 2 to 3 days and expanded in the pluripotent state before differentiation.
iPSC lines used for test and validation purposes were generated from multiple sources and different reprogramming strategies, including mouse embryonic fibroblasts, adult cardiac fibroblasts, or adult tail tip fibroblasts through lentiviral or doxycycline-inducible reprogramming. Specifically, line A was derived from cardiac fibroblasts from Gt(ROSA)26Sor tm1(rtTA*M2)Jae Col1a1 tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae /J mice carrying a doxycycline-inducible cassette for the aforementioned 4 reprogramming factors. Isolated fibroblasts were plated directly onto inactivated feeders and cultured in EmbryoMAX DMEM supplemented with 15% fetal bovine serum, leukemia inhibitory factor, and 2 µg/mL doxycycline, with daily medium changes. Colonies were picked after 2 to 5 weeks and maintained in doxycycline-free medium after passage 4. Line B was generated from mouse embryonic fibroblasts with an integrative approach using lentiviruses expressing Oct4, Sox2, and Klf4 (Open Biosystems). Line C was produced from tail tip fibroblasts, and sample D was derived from cardiac fibroblasts, both using the 3-factor-integrative approach. Colonies were picked between weeks 4 and 9 after infection. Three lines from each of the 6 combinatorial approaches were used for final validation. Undifferentiated cells were used for quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis.
Cell Differentiation
Pluripotent cells were spontaneously differentiated following an embryoid body (EB) formation protocol in differentiation medium with 20% fetal bovine serum in the absence of leukemia inhibitory factor. 18 Drops containing ≈600 cells in 25 µL differentiation medium were deposited on bacteriological plate lids and cultured for 48 hours to force cell aggregation, followed by 48 hours of suspension culture. At day 5 of differentiation, EBs were plated on gelatin and allowed to grow for 6 more days; ≈48 hours after plating (day 7), EBs started displaying areas of rhythmical contraction corresponding to newly formed cardiac cells. Spontaneous contractile activity was quantified in biological triplicates, including 20 to 60 EBs per replicate (total of 90-140 EBs characterized per time point) for a total differentiation time of 11 days. Samples were collected at baseline (day 0), suspension EBs (day 5), and at the end of the differentiation process (day 11). Pluripotent lines used for validation were differentiated using aggrewells. 24 In brief, cells were trypsinized into a single cell suspension and centrifuged in microwell-containing plates at a density of 2.4 million cells to each aggrewell in differentiation medium. Two days later, aggregates were transferred to low adherence plates and cultured in suspension for 48 hours. EBs were then plated onto gelatinized plates, and beating activity was monitored for 20 days. Plates were individually monitored in a blinded fashion; cell line identity was only revealed at the end of the analysis. Statistical relevance of differences in beating activity was probed using general linear model in R programming.
Quantitative Reverse Transcription Polymerase Chain Reaction
cDNA was synthesized with the reverse transcriptase supermix kit from Invitrogen. 18 All quantitative RT-PCR was performed with an Illumina Eco-Real Time PCR system. For data processing, readings were normalized to GAPDH from the same plate. Expression values were made relative to the lowest expression value among all samples for 1 given gene. Error bars represent SEM. Primers included in the predictive panel can be found in Table I in the online-only Data Supplement.
Statistical Methods
Statistical Microarray Data Analysis
Affymetrix Mouse Genome 430 2.0 arrays were used to screen for differential gene expression levels according to standard protocols in the Mayo Clinic Advanced Genomic Technology Center Gene Expression Core. Raw microarray image data were analyzed using several R and Bioconductor packages and custom R scripts for quality assessment/quality control and differential analysis. [25] [26] [27] [28] [29] [30] The quality assessment/quality control process included assessment of the raw microarray images, MAplot, normalized unscaled SE, residual images from the Robust Multi-chip Average model, relative log expression, RNA degradation based on all the probes on the microarray using internal R scripts, and R/Bioconductor packages. Standard Affymetrix quality metrics were also assessed, such as 3´/5´ ratios, background, Scaling factor, control probes, GAPDH, and Percentage Present calls. Differential analysis was performed using the Limma package in R. 31 Differential genes were selected based on P<0.01 after false discovery rate control to correct for multiple comparisons and fold change >4. All the hierarchical clustering analyses to generate the dendrograms were performed using R based on the algorithm of average Euclidean distance. Gene function enrichment analysis on differentially expressed genes was performed using MetaCore (GeneGo) software. [32] [33] [34] Raw microarray data are available in NCBI GEO database under accession number GSE43197.
A 72-gene panel was designed to extract the cardiac component (in terms of gene expression levels) from the mixed population resulting from spontaneous unguided differentiation, enabling comparison with the all-cardiac probes represented in the developmental roadmap. Genes were included based on cardiac-related functions as curated in GenMAPP pathway database and current knowledge of cardiac development. Representative pluripotency and gastrulation markers were included to visualize loss of the undifferentiation state and transition into maturing phenotypes.
Pearson Correlation and Hierarchical Clustering Heatmap
All correlation values in this article are Pearson correlation, which are calculated based on average gene expression across triplicate biological samples at each time point. Calculation and clustering were done using R program functions.
Cardiogenic Score Calculation
The cardiogenic score was calculated based on quantitative RT-PCR values for 12 genes. First, to normalize the scale for individual genes, expression values were recalculated as percentages, using the highest value within each gene as 100%. Genes naturally upregulated in pluripotent stem cells and initial stages of development were designated as positive predictors, whereas genes showing low values in early cardiogenesis were designated as negative predictors. The average contribution for all the negative predictors was subtracted from the average contribution of all the positive predictors, resulting in a composite cardiogenic score.
Results
Natural Cardiogenesis Roadmap Revealed Through High Content Microarray Analysis of Stage-Specific Embryonic Heart Samples
To establish a spatiotemporal expressome of natural cardiogenesis, stage-specific embryonic cardiac structures were dissected, collected, and profiled. Samples ranging from pluripotent cells to adult left and right ventricular tissue, including whole embryos at day E7.5, heart tubes from E8.5 embryos, as well as left and right ventricles, were surgically obtained from developing mice at E9.5, E12.5, E14.5, E18.5, newborns, and adults ( Figure 1A ) and subjected to microarray analysis. Quality assessment/quality control analyses of isolated RNA and microarray raw data ensured that the surgical procedure required for harvesting and the microarray hybridization process did not compromise bioinformatic analysis and data interpretation, as illustrated by parallel slopes in the RNA degradation plots showing comparable good quality for all studied samples ( Figure 1B ). Unsupervised hierarchical clustering based on all the probesets in the microarrays, representing relative distance among samples, defined developmental units grouping precardiac samples (undifferentiated cells and E7.5 whole embryos), heart tube (E8.5 and E9.5), midgestation (E12.5 and E14.5), perinatal (E18.5 and newborn), and adult-derived samples ( Figure 1C ). In this way, a temporally regulated dataset fulfilling stringent quality standards established a cardiogenic roadmap calibrated at discrete developmental stages within natural embryogenesis.
Stage-Specific Expressome Gauges Cardiogenic Potential Among Pluripotent Cell Lines
Nuclear reprogramming allows derivation of iPSC from somatic starting sources. 35 However, varying degrees of cardiogenicity have been reported depending on the reprogramming factors used to reinstate pluripotency. 16, 17 Herein, somatic cells were reprogrammed using the pluripotency factors (SOX2, OCT4, KLF4, and c-MYC; 4-factor-iPSC) or 3 factors (SOX2, OCT4, and KLF4; 3-factor-iPSC) to achieve the pluripotent state according to stringent pluripotency criteria. 16 Using a pseudo-3-dimensional culturing system based on EB formation, pluripotent stem cells were differentiated toward cardiac lineages and monitored for beating activity as a functional surrogate for proper cardiogenesis (Figure 2A ). Beating activity has been shown to correlate with levels of expression of cardiac transcription factors and protein expression 36 and provides a readout of electromechanical integration and functionality of derived cardiac cytotypes. Established R1-ESCs, extensively characterized for pluripotency and cardiac differentiation, [37] [38] [39] were used as a reference pluripotent stem cell line. In agreement with previous in vitro work, 16 contracting cardiac tissue seemed in differentiating 3-factoriPSC following the time-course consistent with R1-ESCs ( Figure 2B ), whereas 4-factor-iPSC did not spontaneously produce a beating cardiac phenotype according to the standardized culture conditions used herein ( Figure 2B ). Despite previously demonstrated cardiogenic potential of 4-factoriPSC in the contexts of diploid aggregation 16 and myocardial regeneration, 40 the in vitro environment was capable of distinguishing the innate difference in the cardiogenic potentials between 3-factor-iPSC and 4-factor-iPSC lines according to production of beating cardiac tissue under equivalent conditions. Based on this phenotypic observation of functional beating activity, we compared the in vitro expression profiles of pluripotent stem cell lines and the established natural cardiac development roadmap to assess whether the assayed cell lines followed canonical differentiation pathways as defined in the natural embryo. To validate the use of the in vitro model system of tissue-specific differentiation, a panel of 72 markers, including pluripotency, gastrulation, and early cardiac and late cardiac markers, was selected from the roadmap of natural cardiogenesis in the mouse model (Table II in the onlineonly Data Supplement and Figure 2C ). The obtained dataset showed age-dependent changes in gene expression as heart development progressed, with pluripotency patterns being replaced by more mature expression patterns ( Figure 2C ). Gene expression heatmap for the same group of cardiacrelated markers in R1-ESCs at days 0, 5, and 11 of spontaneous differentiation ( Figure 2D ) highlighted expression patterns corresponding to developmental stages R1, E7.5, and E12.5-newborn, respectively ( Figure 2C and Figure I in the online-only Data Supplement). These results indicate that in vitro differentiation of ESCs mimics stage-specific cardiogenesis, validating the comparative approach to monitor in vitro cardiac differentiation from bioengineered iPSC according to an embryonic expressome roadmap.
To determine whether the cardiogenic roadmap is capable of distinguishing between high-and low-cardiac potential of iPSC cell clones, expressome profiles for 3-factor-iPSC and 4-factor-iPSC differentiated in vitro were extracted according to the panel of cardiac-related genes ( Figure 2E ) and compared with the reference ESC-derived dataset. The overlay between expressomes derived from pluripotent stem cells uncovered equivalent global gene expression profiles at baseline across the 3 independent pluripotent lines ( Figure 2E, left) . However, as in vitro differentiation progressed, divergent expression profiles became apparent starting at day 5 for 4-factor-iPSC ( Figure I in the online-only Data Supplement), which failed to upregulate key gastrulation (Lhx1), endoderm (Sox17), and early mesendoderm/ cardiac precursor markers (Cxcr4, Kdr, Tbx20, Mesp1, Isl1; Figure 2E , middle) while maintaining expression patterns that preserved the pluripotent fingerprint. Based on correlation values, 4-factor-iPSC showed higher similarity to R1 (undifferentiated cells in roadmap) after 5 days of in vitro differentiation, whereas 3-factor and reference ESC (day 5) advanced toward a gastrulation/precardiac profile similar to natural embryonic structures corresponding to E7.5 ( Figure 2C) . Furthermore, by day 11, the 4-factor-iPSC did not have distinct similarity to any of the assayed embryonic stages, whereas 3-factor-iPSC and ESC acquired an advanced expressome more similar to E12-newborn stages ( Figure 2E , right), indicating progression of cardiac differentiation in vitro. Despite simultaneous downregulation of pluripotencyrelated genes in all 3 groups by day 11, expression of early and late cardiac markers in 4-factor-iPSC failed to reach levels shown for 3-factor-iPS or R1-ESC by the end of the differentiation process ( Figure 2E, right) . On unsupervised hierarchical clustering of the 72-gene set, inconsistent modulation of gene expression resulted in segregation of 4-factoriPSC from both ESCs and 3-factor-iPSC ( Figure 2F) RNA degradation plot Figure 1 . Establishment of a cardiac development roadmap by high content screening of embryonic cardiac tissue. A, Stage-specific samples subjected to microarray analysis included mouse embryonic stem cells, mouse embryonic stage E7.5 whole embryos, heart tubes from E8.5, and independent samples for left and right ventricles (LV and RV) of E9.5, E12.5, E14.5, E18.5, newborn, and adult mouse hearts. B, RNA degradation plot for quality assessment/quality control. Each line represents 1 sample with probes ordered (on x axis) according to relative locations on transcripts. Probe intensities were calculated across whole chip for all probes at that position. Lines were shifted for visualization. C, Unsupervised hierarchical clustering of cardiac development samples based on all the probesets in the microarray, with different tones of the same color representing RV and LV for the same stage. Bar height correlates with differences among samples.
during spontaneous in vitro cardiac differentiation that was incompetent to produce functional cardiac tissue with visible beating activity. This anomalous profile of quality-controlled 4-factor-iPSC cells was independently confirmed when samples were analyzed according to a genome-wide expressome representing overall expression profiles ( Figure II . Eighty-two transcripts were differentially expressed between 3-factor-iPSC and 4-factor-iPSC at day 0, with P values after false discovery rate control at 0.01 and log2-fold change at 2 ( Figure 3A , red dots, and Table III in the online-only Data Supplement). These genes correspond to prioritized cytoskeleton and extracellular matrix remodeling pathways ( Figure 3B ). Downstream effects of the baseline expression profile in 4-factor-reprogrammed cells resulted in magnified differences because in vitro differentiation proceeds through subsequent developmental milestones, with 399 differentially expressed transcripts at day 5 and 726 differentially expressed transcripts by day 11 ( Figure III in the online-only Data Supplement). Functional differences between 3-factor-iPSC and 4-factor-iPSC were noted in extracellular matrix and cytoskeleton remodeling that were persistent throughout differentiation and consistent with dysregulation of epithelial-to-mesenchymal transitionrelated functions and cardiac-related signaling pathways R1 3F 4F R1 3F 4F R1 3F 4F ( Figure III in the online-only Data Supplement). To select the genes uniquely regulated in undifferentiated 4-factor-iPSC that could be responsible for the nonbeating phenotype, pairwise comparisons among the 3 pluripotent lines (3-factor versus R1, 3-factor versus 4-factor, and R1 versus 4-factor) were performed. Resulting lists of differentially expressed transcripts in beating versus nonbeating comparisons (3-factor versus 4-factor and R1 versus 4-factor) were overlapped to identify genes differentially regulated in nonbeating 4-factor-iPSC. Finally, genes from this comparison that were also contained in the 3-factor versus R1 group (both lines were beating) were removed as background noise not involved in regulating the defined outcome (beating), resulting in a list of 27 transcripts, corresponding to 23 genes, differentially regulated in nonbeating 4-factor-iPSC ( Figure 3C ). Thus, genome-wide transcriptome analysis enabled dissection of early mechanisms that are distinctive in cardiogenic dysfunction within 4-factor-iPSC lines and highlights cardiogenic pathways that may be responsible for individual variability between bioengineered stem cells.
Cardiogenic Roadmap Predicts Procardiogenic Outcome at Pluripotent Stage for Individual iPSC Lines
We hypothesized that disruption of cardiac differentiation properties of iPSC cells may be linked to dysregulated expression of 23 genes uniquely patterned in less-cardiogenic cells at the pluripotent stem cell stage ( Figure 3D and Figure IV in the online-only Data Supplement). Gene expression profile for these 23 genes extracted from the comprehensive roadmap revealed a high degree of correlation between early stages of natural embryonic development and cardiogenic cells (3-factor and R1-ESC; Figure 3E and Figure this group of genes in 4-factor-reprogrammed cells highlights precardiogenic programs enabling downstream heart development from the pluripotent stage ( Figure VI in the online-only Data Supplement). Therefore, the cardiogenic roadmap established from natural developmental processes may predict corrupt gene expression patterns and subsequent dysfunctional heart developmental outcomes from iPSC lines.
Composite Index Predicts Cardiac Potential of iPSC Lines
To determine whether the 12 genes identified through unbiased analysis are randomly associated to high/low cardiogenic lines or are mechanistically linked as regulators of cardiogenic variability, an empirical assay was developed. The predictive power of the profile was tested in 4 independent iPSC lines with distinct cardiogenic potential according to the onset of beating activity as a functional surrogate marker ( Figure 4A ) from previously validated cardiogenic (3-factor-iPSC) and less-cardiogenic (4-factor-iPSC) lines as test case examples. The observed beating activity correlated with expression levels of mesendoderm marker Cxcr4 during gastrulation, showing increased expression in early beating iPSC lines. Furthermore, endoderm and ectoderm markers followed opposite expression trends, with Sox1 and Hnf4 being upregulated in early differentiation stages of less-cardiogenic lines ( Figure VII in the online-only Data Supplement). iPSC derived from both adult and embryonic sources were included, as were 2 different reprogramming strategies (lentiviral infection and stable integrated dox-inducible transgenes). The panel of confirmed 12 genes was profiled within each sample at pluripotency stage using quantitative RT-PCR. Genes were categorized as positive predictors (upregulated in cardiogenic 3-factoriPSC/ESCs; Figure 4B ) and negative predictors (upregulated in less-cardiogenic 4-factor-iPSC; Figure 4C ). Contribution of each gene was calculated for each assayed line as described in the Methods section ( Figure Figure 4D ) and negative ( Figure 4E ) predictors was obtained for each iPSC line, revealing higher levels of positive predictor genes in the more cardiogenic lines as well as upregulated negative predictor values in less-cardiogenic 4-factor-iPSC. A composite predictor including contribution from all genes in the predictive panel was then calculated (positive-negative predictors), exposing the final cardiogenic predictive score for each studied line. This cardiogenic score, from pluripotent cells, matched the cardiac differentiation potential according to the functional marker of beating activity for each of the studied lines and was therefore able to anticipate cardiogenicity of independent iPSC lines. To validate this cardiogenic score, values were obtained for a total of 18 reprogrammed pluripotent lines derived from 3 somatic sources (embryonic fibroblasts, tail tip fibroblasts, and cardiac fibroblasts), using either lentiviral or Dox-inducible reprogramming strategies and previously characterized for cardiogenic potential in terms of beating activity as a functional surrogate marker (Figure 4G ). When plotted according to the onset of beating activity, 2 distinctive groups were apparent, with early beating cell lines displaying higher cardiogenic score values and late beating cells linked to lower scores. Based on the receiver-operating characteristic curve analysis, the optimal threshold was set at 13.8, which retained ≈80% sensitivity while still maintaining the specificity and precision at 100% level ( Figure 4H and Figure IX in the online-only Data Supplement). In summary, this PCR platform based on developmentally curated genes discriminates between reprogrammed lines with high and low cardiogenic potential within cells at the pluripotent state.
Discussion
The integration of high-throughput technology and stagespecific approaches created herein a temporally regulated dataset of gene expression throughout natural embryonic cardiac development. Although other nongenetic factors such as the epigenetic state 41 and stochastic phenomena 42 may have a concomitant influence on differentiation outcomes, we here focused on the transcriptional component of the differentiation process, providing a broadly applicable and technically accessible platform that may be leveraged for stage identification, guided differentiation, and comparative bioinformatic applications. The novel information contained in this comprehensive roadmap of normal cardiogenesis allowed us to build a translatable atlas of pathways and networks defining innate mechanisms of cardiogenesis. By isolating the expression matrix for a subset of cardiac-related genes, we established a discrete guide for cardiogenicity used here to gauge and predict the ability of reprogrammed progeny to give rise to cardiac tissue. Specifically, innately cardiogenic iPSC reprogrammed using Oct4, Sox2, and Klf4 lentiviruses were compared with less spontaneously cardiogenic counterparts bioengineered in the presence of the oncogene c-Myc. 16 This fourth component of the reprogramming cocktail has been previously shown to impair the in vitro cardiogenicity of mouse 4-factor-iPSC, whereas preserving their potential for cardiac contribution and repair in vivo, 16, 40 underscoring the importance of contextdependency of the cardiac differentiation process. During early phases of in vitro differentiation of c-Myc-containing cells, delays were observed in the onset of the initial transcriptional programs required to trigger cardiac differentiation according to the developmental roadmap, as demonstrated by the lack of upregulation of precardiac genes after 5 days of in vitro differentiation as well as abnormal clustering of differentiated 4-factor samples with ESC and 3-factor-iPSC at the pluripotent state. Transcriptional amplification of already active genes caused by Myc may explain the impaired transition of 4-factor-iPSC to a procardiogenic state, 43 maintaining instead high levels of pluripotency markers despite being subjected to differentiation conditions. This unique bioinformatics analysis thus identifies failing cardiogenesis, suggesting the importance of early pathways that are sufficient to disrupt onset of canonical developmental processes.
As a proof-of-concept application, we herein demonstrate the use of a developmental roadmap to gauge cardiac potential of pluripotent sources. By contrasting expression profiles of temporally regulated cardiac-related genes between stage-specific embryonic hearts and in vitro differentiated cells, various levels of cardiogenicity among pluripotent cell lines were apparent according to differential expression profiles shortly into initiation of spontaneous differentiation. These disparities further correlated with alterations in essential pathways such as epithelial-to-mesenchymal transition, required for endocardial cushion formation, 44 epicardium development, 45 reparative functions, 46, 47 and cardiosphere generation from heart biopsies, 48 suggesting disruption of these processes that are linked to decreased functional beating activity in 4-factor-iPSC lines.
Differences in known pluripotency markers and tissuespecific expression patterns at the undifferentiated state do not correlate with variable differentiation propensities of ESC lines. 49 Our design using genome-wide bioinformatic approach allows the inclusion of potentially relevant genes whose regulatory roles might not be yet defined. As a result, we describe a panel of genes not previously linked to cardiogenicity and grouped here into a predictive score that is associated, in an impartial way, with variation in the cardiac differentiation ability of reprogrammed iPSC cells. This approach was able to identify a subset of heterogeneous identities with distinct patterning in less-cardiogenic samples. These genes include epithelial keratins (Krt8 and Krt18), 50 inflammation-related chemokine ligands (Cxcl3 and Cxcl5), 51, 52 interferon-induced genes (Ifi44, Ifit1, Ifit3, and Ifi203), a Golgi chaperon (Rtp4), 53 interferon regulator Usp18, 54 metalloprotease Mmp9, and unknown function Klhk13. From these, only metalloproteinase Mmp9, upregulated within poorly cardiogenic cells at day 0, has been demonstrated to be activated in heart disease and remodeling, with low levels improving survival and differentiation of cardiac stem cells. 55, 56 In contrast to previous studies using differentiated progeny to establish the capacities of pluripotent cells, 57 we focused our analysis on undifferentiated samples, allowing faster screening of candidate lines shortly after reprogramming and reducing potential variability attributable to the reprogramming procedures. 58 The prognostic potential of the composite score described in this work was tested in 4-factor-iPSC lines reprogrammed by lentiviral infection or doxycycline induction in fibroblasts from embryonic or adult tissues. A relative value was obtained mapping the relative cardiogenic ability of each undifferentiated line in the framework of the original high and low cardiogenic lines. The delivered ranking faithfully recapitulated the observed cardiac potential in terms of beating activity, across both cell sources and reprogramming strategies, confirming the linearity index-phenotype and therefore its predictive value. We validated these results by applying the cardiogenic score to a total of 18 reprogrammed lines with different origins and reprogrammed using 2 different strategies. Although the linearity between index and phenotype was not strictly conserved, the most cardiogenic lines (early beating) had higher scores than the less-cardiogenic ones (late beating). Based on the receiver-operating characteristic curve analysis, 60% percentile of the score, corresponding to 13.8 in our dataset, led to prediction of the cardiogenic potential of reprogrammed pluripotent lines, with ≈80% sensitivity and 100% specificity and precision. By maximizing the specificity of the cutoff, we ensured selection of high cardiogenic potential in profiled cell lines at the risk of filtering out iPSC lines that demonstrate high levels of beating activity. Application of this score, therefore, would allow discrimination of the 40% most cardiogenic lines by applying a PCR panel, limiting time and resources necessary to reproducibly obtain full cardiac potential via lengthy in vitro differentiation.
Overall, we have established a comprehensive time course of healthy cardiac development that offers a template to define natural differentiation stages, as well as disruptive changes in expression patterns responsible for heart disease or dysfunctional networks resulting in incompetent cardiogenicity in vitro. By combining this unbiased expressome platform with transcriptomes from iPSC lines characterized by high-and low-cardiac differentiation potential, we have developed a tool to forecast cardiogenicity of reprogrammed sources before differentiation. Furthermore, using the genomic analysis strategies described herein may identify and prioritize candidate genes offering a novel approach to determine molecular targets that regulate cardiac phenotype of individual bioengineered stem cells. The novel bioinformatic platform described in this work allows prospective selection of cardiogenic lines for reproducible generation of cardiac derivatives required for theranostic applications and thus opens a new avenue for optimization of stem cell-based regenerative medicine platforms based on bioengineered stem cells.
CLINICAL PERSPECTIVE
Embryonic stem cells and bioengineered induced pluripotent stem cells offer great opportunities for the generation of large amounts of cardiomyocytes for drug discovery, therapeutic application, or diagnostic application. However, stem cell-based cardiogenesis is a complex process including great variability in differentiation potential observed between lines. To address these issues, we report a roadmap of natural cardiogenesis comprising the time course of gene expression profiles characterizing natural heart development from early embryos to the adult heart. This is subsequently used as a guideline to validate stem cell-based differentiation protocols, demonstrating that pluripotent cells recapitulate natural developmental stages as they differentiate toward cardiomyocytes. Leveraging this new platform, we address the variable cardiogenic potential of induced pluripotent stem cell lines by comparing highly and poorly cardiogenic samples at various levels of differentiation to the roadmap of natural cardiogenesis. Through this analysis, we identify genes that are uniquely regulated in low cardiogenic samples and compile them in an index that allows us to predict and select lines with a higher potential for cardiac differentiation. Overall, this comprehensive model of embryonic heart development serves as standard to probe stem cell-based cardiac differentiation, bringing us one step closer to reproducible manufacturing of bona fide cardiomyocytes to be used for clinical and diagnostic endeavors.
